Cancer Chemotherapy and Pharmacology,volume 73,issue 3  (03-2014)

Period of time: 2014年3期

Publisher: Springer Publishing Company

Founded in: 1978

Total resources: 46

ISSN: 0344-5704

Subject: R73 Oncology

Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Cancer Chemotherapy and Pharmacology,volume 73,issue 3

Menu

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study

By Casal Rubio J.,Fírvida-Pérez J.,Lázaro-Quintela M.,Barón-Duarte F.,Alonso-Jáudenes G.,Santomé L.,Afonso-Afonso F.,Amenedo M.,Huidobro G.,Campos-Balea B.,López-Vázquez M.,Vázquez S. in (2014)

Cancer Chemotherapy and Pharmacology,volume 73,issue 3 , Vol. 73, Iss. 3, 2014-03 , pp. 451-457

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies

By Mahadevan Daruka,Sutton Gregory,Arteta-Bulos Rafael,Bowden Chris,Miller Paul,Swart Rachel,Walker Mark,Haluska Paul,Munster Pamela,Marshall John,Hamid Omid,Kurzrock Razelle in (2014)

Cancer Chemotherapy and Pharmacology,volume 73,issue 3 , Vol. 73, Iss. 3, 2014-03 , pp. 467-473

Springer Publishing Company

Abstract Access to resources Recommend Favorite

A phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignancies

By Bruce Justine,Kolesar Jill,Hammers Hans,Stein Mark,Carmichael Lakeesha,Eickhoff Jens,Johnston Susan,Binger Kimberly,Heideman Jennifer,Perlman Scott,Jeraj Robert,Liu Glenn in (2014)

Cancer Chemotherapy and Pharmacology,volume 73,issue 3 , Vol. 73, Iss. 3, 2014-03 , pp. 485-493

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

By Wheler Jennifer,Janku Filip,Falchook Gerald,Jackson Tiffiny,Fu Siqing,Naing Aung,Tsimberidou Apostalia,Moulder Stacy,Hong David,Yang Hui,Piha-Paul Sarina,Atkins Johnique,Garcia-Manero Guillermo,Kurzrock Razelle in (2014)

Cancer Chemotherapy and Pharmacology,volume 73,issue 3 , Vol. 73, Iss. 3, 2014-03 , pp. 495-501

Springer Publishing Company

Abstract Access to resources Recommend Favorite

Age affects pegylated liposomal doxorubicin elimination and tolerability in patients over 70 years old

By Gusella Milena,Bononi Antonio,Modena Yasmina,Bertolaso Laura,Franceschetti Paola,Menon Daniela,Pezzolo Elisa,Barile Carmen,Crepaldi Giorgio,Bolzonella Caterina,Inno Alessandro,Padrini Roberto,Pasini Felice in (2014)

Cancer Chemotherapy and Pharmacology,volume 73,issue 3 , Vol. 73, Iss. 3, 2014-03 , pp. 517-524

Springer Publishing Company

Abstract Access to resources Recommend Favorite